Journal
FRONTIERS IN IMMUNOLOGY
Volume 3, Issue -, Pages -Publisher
FRONTIERS RESEARCH FOUNDATION
DOI: 10.3389/fimmu.2012.00013
Keywords
dendritic cells; vaccine; targeting; dendritic cell subsets; antigen delivery
Categories
Funding
- Australian Research Council
- Howard Hughes Medical Institute
- Bill and Belinda and Gates Foundation
- National Health and Medical Research Council of Australia
Ask authors/readers for more resources
Monoclonal antibodies that recognize cell surface molecules have been used deliver antigenic cargo to dendritic cells (DC) for induction of immune responses. The encouraging anti-tumor immunity elicited using this immunization strategy suggests its suitability for clinical trials. This review discusses the complex network of DC, the functional specialization of DC subsets, the immunological outcomes of targeting different DC subsets and their cell surface receptors, and the requirements for the induction of effective anti-tumor CD4 and CD8 T cell responses that can recognize tumor-specific antigens. Finally, we review preclinical experiments and the progress toward targeting human DC in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available